Key Finding
This is a study protocol for a 150-participant randomized controlled trial testing whether moxibustion plus standard supplements can prevent bone loss better than supplements alone in postmenopausal women with osteopenia, with results pending.
This study is examining whether moxibustion, a traditional Chinese medicine heat therapy, can help prevent bone loss in postmenopausal women with osteopenia (lower than normal bone density that hasn't yet reached osteoporosis levels). Researchers in China are recruiting 150 women to participate in a 12-month trial. Half will receive real moxibustion treatments while the other half receives a placebo version, with neither patients nor outcome assessors knowing which treatment they're receiving. All participants will also take vitamin D3 and calcium supplements as recommended by standard guidelines. The study will measure bone mineral density at the spine, hip, and femoral neck, along with various blood markers related to bone health, bone pain levels, quality of life, and any side effects. Participants will receive 42 treatment sessions over the year. This is a study protocol, meaning the research is planned but results are not yet available. The researchers hope to determine whether adding moxibustion to standard supplements provides additional protection against bone loss compared to supplements alone. If effective, this could offer postmenopausal women a non-drug option for preventing osteoporosis during the critical transition period of osteopenia. The results will be published in medical journals once the study is complete. If you're considering moxibustion for any health condition, seek treatment from a licensed acupuncturist or qualified Traditional Chinese Medicine practitioner.
This randomized, patient-blind, assessor-blind, placebo-controlled trial will evaluate moxibustion as adjuvant therapy for preventing bone loss in postmenopausal women with osteopenia. The study will enroll 150 participants randomized 1:1 to moxibustion treatment (MT) or placebo-moxibustion control (PMC), with both groups receiving guideline-recommended vitamin D3 and calcium supplementation. Participants will undergo 42 treatment sessions over 12 months. The primary outcome is lumbar spine bone mineral density (BMD) at 12 months. Secondary outcomes include femoral neck and total hip BMD, T-scores, bone turnover markers, serum calcium/magnesium/phosphorus/PTH/25-hydroxyvitamin D levels, bone pain intensity, quality of life, osteoporosis/fracture incidence, and adverse events. Analysis will follow intention-to-treat and per-protocol principles. This protocol addresses a significant gap in evidence for moxibustion's role in osteoporosis prevention during the critical osteopenic transition period. Results will inform clinical decision-making regarding integrative approaches to bone health in postmenopausal women at low fracture risk.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Different moxibustion temperatures activate distinct thermosensitive proteins and pathways that influence the phenotypic remodeling of primary lesion cells in rheumatoid arthritis, including fibroblast-like synoviocytes, macrophages, and T cells.
📌 Moxibustion significantly reduced arthritis severity in animal models with large effect sizes (SMD -3.72 for arthritis index) while suppressing pro-inflammatory cytokines and key signaling pathways including NF-κB and NLRP3 inflammasome.
📌 Three transdermal moxibustion compounds—Citral, α-Terpineol, and Borneol—were identified as targeting TNF-α to reduce rheumatoid arthritis through MAPK pathway inhibition and MMP modulation.